The agreement encompasses clinical practice and research in radiotherapy oncology, medical oncology, diagnostic imaging, molecular diagnostics, and R+D+I.
The Champalimaud Foundation, one of the most recognized institutions in the prevention, diagnosis, and treatment of cancer, and Atrys Health, S.A. (BME:ATRY), which focuses on telemedicine and precision oncology, announce an oncology collaboration agreement to jointly perform advanced diagnostic and therapeutic procedures.
Based in Lisbon and a pioneer in the development of advanced biomedical research programs and high-precision radiation treatment techniques, with emphasis on single-dose, hypofractionated extreme radiotherapy (SDRT), the Champalimaud Foundation brings together the best clinical care with an ambitious research programming – activities carried out at the Champalimaud Center for the Unknown (CCU), leading oncology facilities worldwide.
Atrys is a global company dedicated to providing 360º healthcare services that range from prevention and health promotion to precision medical diagnosis and cancer treatment. It is the leader in telediagnostics in Castilian and is recognized in state-of-the-art radiotherapy, with a team of more than 3000 professionals. The company is present in Spain, Portugal, Switzerland, and Latin America.
Under this agreement, the two institutions begin the application of joint protocols and methodologies under the Scientific Coordination of Professor Carlo Greco. Under this agreement, common protocols and methodologies will be applied and patient care will be optimized at each of its centers. On October 6th, Atrys and the Champalimaud Foundation will meet in Santa Maria da Feira to share with the medical community the clinical differentiation involved in patient care, marking the official start of the partnership.
The agreement also provides for the creation of a joint and international committee on tumors, allowing professionals and specialists to interact on a regular basis and jointly study the most complex cases – thus offering a multidisciplinary view and the best alternatives for patients.
The two institutions are also developing a network of clinical trials and will jointly coordinate their teams to carry out multicenter studies that allow the establishment of clinical and scientific evidence. Atrys will complement and update the training of its professionals at the Champalimaud Foundation with the latest innovations. On the 27th of September, the first joint scientific meeting will be held at Atrys Advanced Medical Center, which will be attended by speakers from both institutions, in addition to other national and international speakers.